## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.9% below STRENGTH zone (4.0-10.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (52% of avg), momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Stream Henry Scheinâ€™s J.P. Morgan healthcare talk live on Jan. 13**
- Source: Stock Titan | 20251229T113230 | Neutral | Relevance: 100%
- Henry Schein, Inc. announced its participation in the J.P. Morgan Healthcare Investor Conference on January 13, 2026. The company's presentation will be live-streamed at 3:00 p.m. PST / 6:00 p.m. EST, and replays will be available on their website. Henry Schein, a global provider of healthcare solutions, achieved sales of $12.7 billion in 2024 and serves over 1 million customers worldwide.

**2. Henry Schein to announce next CEO by mid-January**
- Source: MassDevice | 20251229T184852 | Neutral | Relevance: 100%
- Henry Schein (Nasdaq: HSIC) plans to select a new CEO by mid-January 2026 to replace Stanley Bergman, who will retire after 45 years with the company. The selection process follows a significant private equity investment from KKR earlier in 2025 aimed at strategic growth. This transition comes as Henry Schein has made new partnerships and initiatives, including with Amazon Web Services and a share repurchase program.

**3. Henry Schein Joins J.P. Morgan Healthcare Event**
- Source: Dentistry Today | 20251229T141335 | Neutral | Relevance: 100%
- Henry Schein announced it will present at J.P. Morgan's Healthcare Investor Conference on January 13, 2026, in San Francisco. The presentation will be webcast live and replays will be available on their website. Henry Schein, Inc. (Nasdaq: HSIC) provides solutions for healthcare professionals globally.

**4. One Fund Bought Up Henry Schein Stock Amid Record Quarterly Results and a New $200 Million Efficiency Plan**
- Source: The Motley Fool | 20251229T140000 | Bullish | Relevance: 100%
- Zuckerman Investment Group significantly increased its stake in Henry Schein (HSIC) by purchasing 72,040 additional shares, totaling an investment of approximately $3.38 million. This move comes as Henry Schein reported strong third-quarter results, with revenue up 5% to $3.3 billion and adjusted EBITDA rising. The company also announced a new $200 million efficiency plan and substantial share buybacks, making it an attractive long-term investment despite underperforming the broader market.

**5. Marathon Asset Management Ltd Cuts Stock Position in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251229T113230 | Neutral | Relevance: 100%
- Marathon Asset Management Ltd decreased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 26.4% in the third quarter, selling 61,529 shares to hold 171,888 shares worth $11.41 million. Despite Henry Schein beating Q3 earnings expectations and providing solid FY2025 guidance, analysts maintain a "Hold" rating with a consensus price target of $76.92. Institutional ownership of Henry Schein stands at 96.62%, with several other funds increasing their positions significantly.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 14.5 |
| Current P/E | 15.6 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.6% to 0.9% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.90% (CS: 62) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.101x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.44
- **Stop Loss:** $73.80 (3.5% risk)
- **Target:** $79.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 522
- **Position Value:** $39,901.68
- **Portfolio %:** 39.90%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*